Thorsten Joachims named vice provost for AI strategy

Joachims, professor of computer science and information science and director of the Cornell AI initiative, will coordinate AI across research, education and operations.

Discovery illuminates how inflammatory bowel disease promotes colorectal cancer

Research unveiled a chain of immune reactions in the gut driven by a key signaling protein and a surge of white blood cells from the bone marrow.

Americans still see opioid overdose as a crisis

Approximately 88% of adults view opioid overdose deaths as a very serious problem with high agreement across political groups, according to a national survey conducted by Weill Cornell Medicine researchers.

Pre-cancerous states identified in seemingly normal aging tissues

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

Whole-genome sequencing may optimize PARP inhibitor use

The approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments.

Pain-sensing neurons kick-start immune responses

Pain sensing neurons in the gut kindle inflammatory immune responses that cause allergies and asthma, according to a new study by Weill Cornell Medicine.

Gary Koretzky ’78 named VP for research

Dr. Gary Koretzky ’78 has been appointed vice provost for research for Cornell’s Ithaca, Cornell Tech and AgriTech campuses, effective Dec. 15, 2025. He has been serving in an interim role since February 2025.

Urologist breaks the silence on women’s pelvic floor disorders

Though pelvic floor disorders happen when the muscles and tissues that support the bladder, bowel and uterus weaken or don’t work properly, and affect one-third of all women, they are not a normal part of aging.

Cornell-developed particles supercharge cancer immunotherapy

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy.